Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...
Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback